RxDoctor Payments Data

Paul Rothwell, MD

Family Medicine · Yukon, OKNPI 1306818984

Payments from drug & device makers

$4,080in general payments, 2019–2025

Across 244 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$468
  • AstraZeneca$425
  • Pfizer$392
  • Lilly USA, LLC$389
  • Otsuka America Pharmaceutical, Inc.$382
  • GSK$297
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,080100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,080 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$166,917
Medicare patients
333
Services billed
6,758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$53,291
MounjaroTirzepatide38$44,235
JardianceEmpagliflozin32$41,722
EliquisApixaban31$27,763
FarxigaDapagliflozin Propanediol38$25,718
TrulicityDulaglutide16$19,867
JanumetSitagliptin Phos/Metformin Hcl16$13,827
MyrbetriqMirabegron16$11,682
JanuviaSitagliptin Phosphate17$10,254
Liothyronine Sodium278$6,744
Dexlansoprazole DrDexlansoprazole15$6,474
Levothyroxine Sodium735$5,872
Epinephrine15$3,437
Omeprazole76$3,203
Testosterone Cypionate74$3,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$389$64,10254 claims
Novo NordiskOzempic$243$53,29142 claims
Boehringer IngelheimJardiance$46$41,72232 claims
PfizerEliquis$392$27,76331 claims
AstraZenecaFarxiga$425$25,71838 claims
MerckJanumet, Januvia$39$24,08033 claims
Astellas Pharma US IncMyrbetriq$119$11,68216 claims
AbbVieArmour Thyroid, Synthroid$468$4,17872 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Yukon

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →